Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab
Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced non-small cell lung cancer (NSCLC), although patient survival is still unsatisfactory. Accurate predictive markers capable of personalizing the treatment of patients with NSCLC are still lacking. Circulating extracell...
Saved in:
| Published in | Clinical and experimental medicine Vol. 24; no. 1; p. 182 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Cham
Springer International Publishing
06.08.2024
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1591-9528 1591-8890 1591-9528 |
| DOI | 10.1007/s10238-024-01427-8 |
Cover
| Abstract | Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced non-small cell lung cancer (NSCLC), although patient survival is still unsatisfactory. Accurate predictive markers capable of personalizing the treatment of patients with NSCLC are still lacking. Circulating extracellular vesicles involved in cell-to-cell communications through miRNAs (EV-miRs) transfer are promising markers. Plasma from 245 patients with advanced NSCLC who received nivolumab as second-line therapy was collected and analyzed. EV-miRnome was profiled on 174/245 patients by microarray platform, and selected EV-miRs were validated by qPCR. A prognostic model combining EV-miR and clinical variables was built using stepwise Cox regression analysis and tested on an independent patient cohort (71/245). EV-
PD-L1
gene copy number was assessed by digital PCR. For 54 patients with disease control, EV-miR changes at best response
versus
baseline were investigated by microarray and validated by qPCR. EV-miRNome profiling at baseline identified two EV-miRs (miR-181a-5p and miR-574-5p) that, combined with performance status, are capable of discriminating patients unlikely from those that are likely to benefit from immunotherapy (median overall survival of 4 months or higher than 9 months, respectively). EV-PD-L1 digital evaluation reported higher baseline copy number in patients at increased risk of mortality, without improving the prognostic score. Best response EV-miRNome profiling selected six deregulated EV-miRs (miR19a-3p, miR-20a-5p, miR-142-3p, miR-1260a, miR-1260b, and miR-5100) in responding patients. Their longitudinal monitoring highlighted a significant downmodulation already in the first treatment cycles, which lasted more than 6 months. Our results demonstrate that EV-miRs are promising prognostic markers for NSCLC patients treated with nivolumab. |
|---|---|
| AbstractList | Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced non-small cell lung cancer (NSCLC), although patient survival is still unsatisfactory. Accurate predictive markers capable of personalizing the treatment of patients with NSCLC are still lacking. Circulating extracellular vesicles involved in cell-to-cell communications through miRNAs (EV-miRs) transfer are promising markers. Plasma from 245 patients with advanced NSCLC who received nivolumab as second-line therapy was collected and analyzed. EV-miRnome was profiled on 174/245 patients by microarray platform, and selected EV-miRs were validated by qPCR. A prognostic model combining EV-miR and clinical variables was built using stepwise Cox regression analysis and tested on an independent patient cohort (71/245). EV-
PD-L1
gene copy number was assessed by digital PCR. For 54 patients with disease control, EV-miR changes at best response
versus
baseline were investigated by microarray and validated by qPCR. EV-miRNome profiling at baseline identified two EV-miRs (miR-181a-5p and miR-574-5p) that, combined with performance status, are capable of discriminating patients unlikely from those that are likely to benefit from immunotherapy (median overall survival of 4 months or higher than 9 months, respectively). EV-PD-L1 digital evaluation reported higher baseline copy number in patients at increased risk of mortality, without improving the prognostic score. Best response EV-miRNome profiling selected six deregulated EV-miRs (miR19a-3p, miR-20a-5p, miR-142-3p, miR-1260a, miR-1260b, and miR-5100) in responding patients. Their longitudinal monitoring highlighted a significant downmodulation already in the first treatment cycles, which lasted more than 6 months. Our results demonstrate that EV-miRs are promising prognostic markers for NSCLC patients treated with nivolumab. Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced non-small cell lung cancer (NSCLC), although patient survival is still unsatisfactory. Accurate predictive markers capable of personalizing the treatment of patients with NSCLC are still lacking. Circulating extracellular vesicles involved in cell-to-cell communications through miRNAs (EV-miRs) transfer are promising markers. Plasma from 245 patients with advanced NSCLC who received nivolumab as second-line therapy was collected and analyzed. EV-miRnome was profiled on 174/245 patients by microarray platform, and selected EV-miRs were validated by qPCR. A prognostic model combining EV-miR and clinical variables was built using stepwise Cox regression analysis and tested on an independent patient cohort (71/245). EV-PD-L1 gene copy number was assessed by digital PCR. For 54 patients with disease control, EV-miR changes at best response versus baseline were investigated by microarray and validated by qPCR. EV-miRNome profiling at baseline identified two EV-miRs (miR-181a-5p and miR-574-5p) that, combined with performance status, are capable of discriminating patients unlikely from those that are likely to benefit from immunotherapy (median overall survival of 4 months or higher than 9 months, respectively). EV-PD-L1 digital evaluation reported higher baseline copy number in patients at increased risk of mortality, without improving the prognostic score. Best response EV-miRNome profiling selected six deregulated EV-miRs (miR19a-3p, miR-20a-5p, miR-142-3p, miR-1260a, miR-1260b, and miR-5100) in responding patients. Their longitudinal monitoring highlighted a significant downmodulation already in the first treatment cycles, which lasted more than 6 months. Our results demonstrate that EV-miRs are promising prognostic markers for NSCLC patients treated with nivolumab. Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced non-small cell lung cancer (NSCLC), although patient survival is still unsatisfactory. Accurate predictive markers capable of personalizing the treatment of patients with NSCLC are still lacking. Circulating extracellular vesicles involved in cell-to-cell communications through miRNAs (EV-miRs) transfer are promising markers. Plasma from 245 patients with advanced NSCLC who received nivolumab as second-line therapy was collected and analyzed. EV-miRnome was profiled on 174/245 patients by microarray platform, and selected EV-miRs were validated by qPCR. A prognostic model combining EV-miR and clinical variables was built using stepwise Cox regression analysis and tested on an independent patient cohort (71/245). EV-PD-L1 gene copy number was assessed by digital PCR. For 54 patients with disease control, EV-miR changes at best response versus baseline were investigated by microarray and validated by qPCR. EV-miRNome profiling at baseline identified two EV-miRs (miR-181a-5p and miR-574-5p) that, combined with performance status, are capable of discriminating patients unlikely from those that are likely to benefit from immunotherapy (median overall survival of 4 months or higher than 9 months, respectively). EV-PD-L1 digital evaluation reported higher baseline copy number in patients at increased risk of mortality, without improving the prognostic score. Best response EV-miRNome profiling selected six deregulated EV-miRs (miR19a-3p, miR-20a-5p, miR-142-3p, miR-1260a, miR-1260b, and miR-5100) in responding patients. Their longitudinal monitoring highlighted a significant downmodulation already in the first treatment cycles, which lasted more than 6 months. Our results demonstrate that EV-miRs are promising prognostic markers for NSCLC patients treated with nivolumab.Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced non-small cell lung cancer (NSCLC), although patient survival is still unsatisfactory. Accurate predictive markers capable of personalizing the treatment of patients with NSCLC are still lacking. Circulating extracellular vesicles involved in cell-to-cell communications through miRNAs (EV-miRs) transfer are promising markers. Plasma from 245 patients with advanced NSCLC who received nivolumab as second-line therapy was collected and analyzed. EV-miRnome was profiled on 174/245 patients by microarray platform, and selected EV-miRs were validated by qPCR. A prognostic model combining EV-miR and clinical variables was built using stepwise Cox regression analysis and tested on an independent patient cohort (71/245). EV-PD-L1 gene copy number was assessed by digital PCR. For 54 patients with disease control, EV-miR changes at best response versus baseline were investigated by microarray and validated by qPCR. EV-miRNome profiling at baseline identified two EV-miRs (miR-181a-5p and miR-574-5p) that, combined with performance status, are capable of discriminating patients unlikely from those that are likely to benefit from immunotherapy (median overall survival of 4 months or higher than 9 months, respectively). EV-PD-L1 digital evaluation reported higher baseline copy number in patients at increased risk of mortality, without improving the prognostic score. Best response EV-miRNome profiling selected six deregulated EV-miRs (miR19a-3p, miR-20a-5p, miR-142-3p, miR-1260a, miR-1260b, and miR-5100) in responding patients. Their longitudinal monitoring highlighted a significant downmodulation already in the first treatment cycles, which lasted more than 6 months. Our results demonstrate that EV-miRs are promising prognostic markers for NSCLC patients treated with nivolumab. Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced non-small cell lung cancer (NSCLC), although patient survival is still unsatisfactory. Accurate predictive markers capable of personalizing the treatment of patients with NSCLC are still lacking. Circulating extracellular vesicles involved in cell-to-cell communications through miRNAs (EV-miRs) transfer are promising markers. Plasma from 245 patients with advanced NSCLC who received nivolumab as second-line therapy was collected and analyzed. EV-miRnome was profiled on 174/245 patients by microarray platform, and selected EV-miRs were validated by qPCR. A prognostic model combining EV-miR and clinical variables was built using stepwise Cox regression analysis and tested on an independent patient cohort (71/245). EV-PD-L1 gene copy number was assessed by digital PCR. For 54 patients with disease control, EV-miR changes at best response versus baseline were investigated by microarray and validated by qPCR. EV-miRNome profiling at baseline identified two EV-miRs (miR-181a-5p and miR-574-5p) that, combined with performance status, are capable of discriminating patients unlikely from those that are likely to benefit from immunotherapy (median overall survival of 4 months or higher than 9 months, respectively). EV-PD-L1 digital evaluation reported higher baseline copy number in patients at increased risk of mortality, without improving the prognostic score. Best response EV-miRNome profiling selected six deregulated EV-miRs (miR19a-3p, miR-20a-5p, miR-142-3p, miR-1260a, miR-1260b, and miR-5100) in responding patients. Their longitudinal monitoring highlighted a significant downmodulation already in the first treatment cycles, which lasted more than 6 months. Our results demonstrate that EV-miRs are promising prognostic markers for NSCLC patients treated with nivolumab. |
| ArticleNumber | 182 |
| Author | Longo, Luca Biello, Federica Rijavec, Erika Marconi, Silvia Dal Bello, Maria Giovanna Tagliamento, Marco Barletta, Giulia Metro, Giulio Vanni, Irene Ludovini, Vienna Novello, Silvia Guana, Francesca Zullo, Lodovica Santamaria, Sara Baraibar, Iosune Passiglia, Francesco Rossi, Giovanni Dellepiane, Chiara Coco, Simona Baglivo, Sara Genova, Carlo Alama, Angela Chiari, Rita Chiorino, Giovanna Ostano, Paola Gil-Bazo, Ignacio Grossi, Francesco Rivoltini, Licia |
| Author_xml | – sequence: 1 givenname: Carlo surname: Genova fullname: Genova, Carlo organization: UOC Clinica Di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Dipartimento Di Medicina Interna E Specialità Mediche (DiMI), Università Degli Studi Di Genova – sequence: 2 givenname: Silvia surname: Marconi fullname: Marconi, Silvia organization: UOS Tumori Polmonari, IRCCS Ospedale Policlinico San Martino – sequence: 3 givenname: Giovanna surname: Chiorino fullname: Chiorino, Giovanna email: giovanna.chiorino@fondazionetempia.org organization: Laboratory of Cancer Genomics, Fondazione Edo Ed Elvo Tempia – sequence: 4 givenname: Francesca surname: Guana fullname: Guana, Francesca organization: Laboratory of Cancer Genomics, Fondazione Edo Ed Elvo Tempia – sequence: 5 givenname: Paola surname: Ostano fullname: Ostano, Paola organization: Laboratory of Cancer Genomics, Fondazione Edo Ed Elvo Tempia – sequence: 6 givenname: Sara surname: Santamaria fullname: Santamaria, Sara organization: UOC Clinica Di Oncologia Medica, IRCCS Ospedale Policlinico San Martino – sequence: 7 givenname: Giovanni surname: Rossi fullname: Rossi, Giovanni organization: UOC Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino – sequence: 8 givenname: Irene surname: Vanni fullname: Vanni, Irene organization: Genetica Oncologica, IRCCS Ospedale Policlinico San Martino – sequence: 9 givenname: Luca surname: Longo fullname: Longo, Luca organization: UOS Tumori Polmonari, IRCCS Ospedale Policlinico San Martino – sequence: 10 givenname: Marco surname: Tagliamento fullname: Tagliamento, Marco organization: Dipartimento Di Medicina Interna E Specialità Mediche (DiMI), Università Degli Studi Di Genova – sequence: 11 givenname: Lodovica surname: Zullo fullname: Zullo, Lodovica organization: UOS Tumori Polmonari, IRCCS Ospedale Policlinico San Martino – sequence: 12 givenname: Maria Giovanna surname: Dal Bello fullname: Dal Bello, Maria Giovanna organization: UOS Tumori Polmonari, IRCCS Ospedale Policlinico San Martino – sequence: 13 givenname: Chiara surname: Dellepiane fullname: Dellepiane, Chiara organization: UOC Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino – sequence: 14 givenname: Angela surname: Alama fullname: Alama, Angela organization: UOS Tumori Polmonari, IRCCS Ospedale Policlinico San Martino – sequence: 15 givenname: Erika surname: Rijavec fullname: Rijavec, Erika organization: Medical Oncology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico – sequence: 16 givenname: Vienna surname: Ludovini fullname: Ludovini, Vienna organization: Department of Medical Oncology, Santa Maria Della Misericordia Hospital – sequence: 17 givenname: Giulia surname: Barletta fullname: Barletta, Giulia organization: UOC Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino – sequence: 18 givenname: Francesco surname: Passiglia fullname: Passiglia, Francesco organization: Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital – sequence: 19 givenname: Giulio surname: Metro fullname: Metro, Giulio organization: Department of Medical Oncology, Santa Maria Della Misericordia Hospital – sequence: 20 givenname: Sara surname: Baglivo fullname: Baglivo, Sara organization: Department of Medical Oncology, Santa Maria Della Misericordia Hospital – sequence: 21 givenname: Rita surname: Chiari fullname: Chiari, Rita organization: Azienda Ospedaliera “Ospedali Riuniti Marche Nord” – sequence: 22 givenname: Licia surname: Rivoltini fullname: Rivoltini, Licia organization: Unit of Immunotherapy, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori – sequence: 23 givenname: Federica surname: Biello fullname: Biello, Federica organization: Oncology Unit, Azienda Ospedaliera Universitaria Maggiore Della Carità – sequence: 24 givenname: Iosune surname: Baraibar fullname: Baraibar, Iosune organization: Department of Oncology, Clínica Universidad de Navarra, Program in Solid Tumors, Center for Applied Medical Research and Navarra Institute for Health Research, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) – sequence: 25 givenname: Ignacio surname: Gil-Bazo fullname: Gil-Bazo, Ignacio organization: Department of Oncology, Clínica Universidad de Navarra, Program in Solid Tumors, Center for Applied Medical Research and Navarra Institute for Health Research, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) – sequence: 26 givenname: Silvia surname: Novello fullname: Novello, Silvia organization: Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital – sequence: 27 givenname: Francesco surname: Grossi fullname: Grossi, Francesco organization: Division of Medical Oncology, Department of Medicine and Surgery, Ospedale Di Circolo E Fondazione Macchi, ASST Dei Sette Laghi – sequence: 28 givenname: Simona surname: Coco fullname: Coco, Simona email: simona.coco@hsanmartino.it organization: UOS Tumori Polmonari, IRCCS Ospedale Policlinico San Martino |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39105937$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUuPFCEUhYkZ4zz0D7gwJG7clHILKGBlTGd8JB1NfKwJRVM9jNVQAtU6_37o7nEcZzEruLnfuZzLOUVHIQaH0HMgr4EQ8SYDaalsSMsaAqwVjXyEToAraBRv5dGd-zE6zfmSEOCSkifomCogXFFxgqbzPyUZ68ZxHk3CW5e9HV3GG_-14YI1fMImrPYlSDD7OuMpxXWIuXiLNyb9dCljH_Dnb4vlAk-meBdKxiU5U9wK__blAge_jeO8Mf1T9HgwY3bPbs4z9OP9-ffFx2b55cOnxbtlY5ngpZGi7QdLYUU7qnomhRJ26ID1rRq6gQFTgxJE1l5PiGNEckEpdNbwTjpDLT1Dbw9zp7nfuJWtlpIZ9ZR8dXylo_H6_07wF3odtxqAEsqoqBNe3UxI8dfsctEbn3c_ZYKLc9aUSMWBCkYr-vIeehnnFOp-e0p2LW-hUi_uWrr18jeNCrQHwKaYc3LDLQJE7yLXh8h1jVzvI9eyiuQ9kfWlZhB3a_nxYSk9SHN9J6xd-mf7AdU1pl--Ug |
| CitedBy_id | crossref_primary_10_3390_life14121608 crossref_primary_10_1177_20503121241289290 crossref_primary_10_1186_s12964_024_01934_x crossref_primary_10_1016_j_heliyon_2024_e36890 |
| Cites_doi | 10.1007/s10585-020-10062-y 10.1016/j.lungcan.2022.09.004 10.3390/cancers14143412 10.1016/j.gene.2023.147177 10.1016/j.lfs.2016.03.002 10.3390/cancers13246252 10.1186/s12943-019-0959-5 10.1371/journal.pone.0136133 10.1007/978-1-60761-944-4_8 10.1158/1078-0432.CCR-17-0577 10.1186/s12979-021-00240-1 10.1155/2016/8394960 10.3390/cells12060832 10.1002/jcp.29578 10.7150/ijms.44377 10.1038/s41419-022-04640-z 10.1111/cas.15268 10.1038/s41419-021-04024-9 10.1016/j.jtho.2020.05.022 10.1093/nar/gkv403 10.1186/s12859-019-3105-x 10.1038/s41598-018-24531-8 10.1038/s41698-022-00262-y 10.3390/jcm8101566 10.3389/fphar.2019.01500 10.3390/cancers12051125 10.1016/j.celrep.2017.05.015 10.2147/CMAR.S272140 10.1016/j.cell.2007.03.008 10.1056/NEJMoa1507643 10.1002/mc.22935 10.3233/CBM-190156 10.3390/cancers12010017 10.21037/tcr.2019.11.19 10.1038/bjc.2018.9 10.3233/CBM-170350 10.1038/s41580-020-0251-y 10.1080/0284186X.2018.1465585 10.1056/NEJMoa1504627 10.7150/ijms.43500 10.3390/ijms21041440 10.1016/j.drudis.2017.03.004 10.1002/eji.201444798 10.18632/oncotarget.2118 10.1016/j.jim.2014.06.007 10.1038/s41467-018-05552-3 10.4049/jimmunol.1100835 10.1186/1755-8794-4-31 10.1016/j.omtn.2019.04.017 10.3390/molecules19021568 10.18632/oncotarget.6338 10.1038/nrg3198 10.1002/jso.23312 10.1007/978-981-15-3266-5_19 10.1126/scitranslmed.aaz5618 10.1097/JTO.0b013e318208c785 10.1038/srep35714 10.1002/cam4.1238 10.1001/jamaoncol.2016.0639 10.3109/10799893.2014.903418 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 2024 |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 2024 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TK H94 K9. 7X8 5PM |
| DOI | 10.1007/s10238-024-01427-8 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Neurosciences Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1591-9528 |
| ExternalDocumentID | PMC11303437 39105937 10_1007_s10238_024_01427_8 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Compagnia di San Paolo grantid: 2017-0529 funderid: http://dx.doi.org/10.13039/100007388 – fundername: Bristol-Myers Squibb grantid: CA209-828-BMS funderid: http://dx.doi.org/10.13039/100002491 – fundername: Ministero della Salute grantid: 5×1000 funds: 2018-2019; CO-2016-02361470; Ricerca Corrente 2022, RRC 2022 funderid: http://dx.doi.org/10.13039/501100003196 – fundername: Compagnia di San Paolo grantid: 2017-0529 – fundername: Ministero della Salute grantid: Ricerca Corrente 2022, RRC 2022 – fundername: Ministero della Salute grantid: 5×1000 funds: 2018-2019 – fundername: Ministero della Salute grantid: CO-2016-02361470 – fundername: Bristol-Myers Squibb grantid: CA209-828-BMS |
| GroupedDBID | --- -5E -5G -BR -EM -~C .86 .VR 06C 06D 0R~ 0VY 1N0 203 29B 29~ 2J2 2JN 2JY 2KG 2LR 2~H 30V 36B 4.4 406 408 409 40D 40E 5VS 67Z 6NX 875 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AAHNG AAIAL AAJKR AAJSJ AAKKN AANZL AARTL AATVU AAUYE AAWCG AAYIU AAYQN AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABEEZ ABFTV ABHLI ABHQN ABIPD ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABWNU ABXPI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEFQL AEGAL AEGNC AEJHL AEJRE AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHIZS AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AITGF AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BGNMA C6C CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBLON EBS EIOEI EMB EMOBN ESBYG F5P FEDTE FERAY FFXSO FIGPU FNLPD FRRFC FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS HF~ HG5 HG6 HLICF HMJXF HQYDN HRMNR HVGLF I09 IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KOV KPH LAS LLZTM M4Y MA- N9A NB0 NPVJJ NQJWS NU0 O93 O9I O9J OAM P2P P9S PF0 QOR QOS R89 R9I ROL RPX RSV S16 S27 S37 S3B SAP SDH SHX SISQX SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 TSG TSK TSV TT1 TUC U2A U9L UG4 UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z87 ZMTXR ZOVNA AAFWJ AASML AAYXX ABDBE ABFSG ACSTC AEZWR AFGXO AFHIU AHPBZ AHWEU AIXLP AYFIA CITATION EBD MK0 CGR CUY CVF ECM EIF NPM 7T5 7TK 7X7 8G5 GUQSH H94 K9. M2O PROAC Q2X 7X8 5PM |
| ID | FETCH-LOGICAL-c475t-872bfc31d3639b48797cf614b29f6f4149f970839bb00e408573316ca568ea3c3 |
| IEDL.DBID | AGYKE |
| ISSN | 1591-9528 1591-8890 |
| IngestDate | Thu Aug 21 18:31:55 EDT 2025 Thu Sep 04 17:21:40 EDT 2025 Thu Sep 25 00:43:40 EDT 2025 Wed Feb 19 02:03:03 EST 2025 Tue Jul 01 02:50:38 EDT 2025 Thu Apr 24 23:04:41 EDT 2025 Fri Feb 21 02:38:03 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Immune checkpoint inhibitor Nivolumab Non-small cell lung cancer (NSCLC) Prognosis score miR-574-5p and miR-181a-5p Pluripotency of stem cell Extracellular vesicle miRNA Toll-like receptor |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c475t-872bfc31d3639b48797cf614b29f6f4149f970839bb00e408573316ca568ea3c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://link.springer.com/10.1007/s10238-024-01427-8 |
| PMID | 39105937 |
| PQID | 3089862521 |
| PQPubID | 43686 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11303437 proquest_miscellaneous_3089513743 proquest_journals_3089862521 pubmed_primary_39105937 crossref_primary_10_1007_s10238_024_01427_8 crossref_citationtrail_10_1007_s10238_024_01427_8 springer_journals_10_1007_s10238_024_01427_8 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-08-06 |
| PublicationDateYYYYMMDD | 2024-08-06 |
| PublicationDate_xml | – month: 08 year: 2024 text: 2024-08-06 day: 06 |
| PublicationDecade | 2020 |
| PublicationPlace | Cham |
| PublicationPlace_xml | – name: Cham – name: Italy – name: Milano |
| PublicationTitle | Clinical and experimental medicine |
| PublicationTitleAbbrev | Clin Exp Med |
| PublicationTitleAlternate | Clin Exp Med |
| PublicationYear | 2024 |
| Publisher | Springer International Publishing Springer Nature B.V |
| Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V |
| References | Li, Chau, Ebert, Sylvester, Min, Liu (CR45) 2007; 129 Xue, Zhang, Li, Liu, Yin, Qu (CR49) 2020; 2020 Saito, Okita, Fusaki, Sabel, Chang, Ito (CR27) 2016; 2016 Chang, Tsai, Hung, Wu, Tsai, Huang (CR41) 2021; 13 Ye, Li, Luo, Huang, Chen, Zhang (CR62) 2014; 5 Cichocki, Bjordahl, Gaidarova, Mahmood, Abujarour, Wang (CR69) 2020; 12 Lawson, Dickman, Towle, Jabalee, Javer, Garnis (CR60) 2019; 58 Rossi, Russo, Tagliamento, Tuzi, Nigro, Vallome (CR2) 2020; 12 Licursi, Conte, Fiscon, Paci (CR24) 2019; 20 Dobbin, Simon (CR25) 2011; 4 Giallombardo, Chacártegui Borrás, Castiglia, Van Der Steen, Mertens, Pauwels (CR26) 2016; 111 Xia, Wei, Hu, Zhou, Lu, Zhan (CR59) 2020; 235 Genova, Boccardo, Mora, Rijavec, Biello, Rossi (CR5) 2019; 8 Vanni, Alama, Grossi, Dal Bello, Coco (CR12) 2017; 22 Zou, Chen, Ge, Qu, Cao, Kang (CR36) 2019; 26 Jiang, Zhou, Shen, Ning, Wu, Jiang (CR65) 2022; 13 Brahmer, Reckamp, Baas, Crinò, Eberhardt, Poddubskaya (CR1) 2015; 373 Halvorsen, Sandhu, Sprauten, Flote, Kure, Brustugun (CR8) 2018; 57 Ye, Li, Kim, Hu, Jadhav, Weyand (CR44) 2018; 9 Nik Mohamed Kamal, Shahidan (CR11) 2019; 10 Li, Li, Diao, Wang, Ye, Hao (CR38) 2021; 13 Li, Li, Guo, Xu, Xia, Liu (CR52) 2012; 7 Bianchi, Alexiadis, Camisaschi, Truini, Centonze, Milione (CR67) 2020; 21 Sacher, Gandhi (CR4) 2016; 2 Siddika, Heinemann (CR31) 2020; 8 Peng, Yu, Wu, Wu, Pi, Chen (CR15) 2020; 8 Marconi, Croce, Chiorino, Rossi, Guana, Profumo (CR28) 2022; 14 Yang, Pi, Yu, Fan, Peng, Zhang (CR35) 2021; 38 Pritchard, Cheng, Tewari (CR29) 2012; 13 O’Brien, Breyne, Ughetto, Laurent, Breakefield (CR55) 2020; 21 Muller, Hong, Stolz, Watkins, Whiteside (CR19) 2014; 411 Taylor, Balko (CR64) 2022; 13 Ge, Zhou, Lu, Bai, Xie, Lu (CR18) 2014; 19 Zhang, Sai, Wang, Wang, Wang, Zheng (CR58) 2019; 18 Leong, Sullivan, Fehniger (CR46) 2014; 44 Jin, Chen, Chen, Fei, Chen, Cai (CR40) 2017; 23 Cichocki, Felices, McCullar, Presnell, Al-Attar, Lutz (CR47) 2011; 187 Takeda, Kataoka, Yamagishi, Ogawa, Seya, Matsumoto (CR68) 2017; 19 Tung, Boardman, Sen, Letizia, Peng, Cianci (CR42) 2018; 8 Foss, Sima, Ugolini, Neri, Allen, Weiss (CR53) 2011; 6 Yang, Wu, Zhang, Jiang, Fan, Fang (CR66) 2014; 34 Lin, Chen, Lin, Lin, Lin, Chen (CR57) 2013; 107 Rajakumar, Horos, Jehn, Schenz, Muley, Pelea (CR10) 2022; 6 Han, Li, Zhang, Guo, Li, Zhang (CR39) 2020; 17 Borghaei, Paz-Ares, Horn, Spigel, Steins, Ready (CR3) 2015; 373 Shi, Zhou, Ye, Chen, Zheng, Fang (CR48) 2017; 20 Li, Lin, Chen, Liu, Dian, Hao (CR63) 2020; 17 Dai, Li, Fan, Tan, Wang, Jin (CR32) 2019; 16 Peng, Wang, Li, Zhao, Huang, Gu (CR54) 2016; 151 Enderle, Spiel, Coticchia, Berghoff, Mueller, Schlumpberger (CR20) 2015; 10 Xu, Zhu, Tao, Ye (CR56) 2018; 7 Rijavec, Coco, Genova, Rossi, Longo, Grossi (CR6) 2019; 12 Shukuya, Ghai, Amann, Okimoto, Shilo, Kim (CR14) 2020; 15 Genova, Tasso, Rosa, Rossi, Reverberi, Fontana (CR21) 2023; 12 Chen, Tan, Wong, Fekete, Halsey (CR30) 2011; 687 Hisakane, Seike, Sugano, Matsuda, Kashiwada, Nakamichi (CR16) 2023; 857 Kim, Ye, Weyand, Goronzy (CR43) 2021; 18 Vlachos, Zagganas, Paraskevopoulou, Georgakilas, Karagkouni, Vergoulis (CR23) 2015; 43 Del Re, Marconcini, Pasquini, Rofi, Vivaldi, Bloise (CR17) 2018; 118 Kim, Park, Choi, Kang, Kim, Pack (CR61) 2021; 12 Zhou, Zhou, Yin, Guo, Hu, Jiang (CR51) 2015; 6 Zhang, Goto, Yagishita, Shinno, Mizuno, Watanabe (CR9) 2022; 173 CR22 Li, Wang, Zhang, Tang, Liu, Dai (CR34) 2015; 10 Gao, Yuan, Yuan, Yuan, Wang (CR33) 2020; 9 Wang, Huang, Lu, Wang, Chen, Huang (CR37) 2022; 113 Hu, Zhang, Chen (CR13) 2020; 1248 Zhou, Zhou, Yin, Guo, Hu, Jiang (CR50) 2016; 6 Schwarzenbach, Gahan (CR7) 2019; 5 KM Foss (1427_CR53) 2011; 6 K O’Brien (1427_CR55) 2020; 21 W-A Chang (1427_CR41) 2021; 13 Z Ye (1427_CR44) 2018; 9 H Borghaei (1427_CR3) 2015; 373 Q Li (1427_CR52) 2012; 7 C Chen (1427_CR30) 2011; 687 X Zhang (1427_CR58) 2019; 18 Y Takeda (1427_CR68) 2017; 19 S Marconi (1427_CR28) 2022; 14 X Jin (1427_CR40) 2017; 23 H Saito (1427_CR27) 2016; 2016 J Lawson (1427_CR60) 2019; 58 T Rajakumar (1427_CR10) 2022; 6 M Giallombardo (1427_CR26) 2016; 111 J Li (1427_CR63) 2020; 17 V Licursi (1427_CR24) 2019; 20 1427_CR22 C Genova (1427_CR5) 2019; 8 Z Han (1427_CR39) 2020; 17 I Vanni (1427_CR12) 2017; 22 Z Li (1427_CR38) 2021; 13 AR Halvorsen (1427_CR8) 2018; 57 T Siddika (1427_CR31) 2020; 8 WX Xue (1427_CR49) 2020; 2020 CC Pritchard (1427_CR29) 2012; 13 BC Taylor (1427_CR64) 2022; 13 X Wang (1427_CR37) 2022; 113 C Kim (1427_CR43) 2021; 18 D Enderle (1427_CR20) 2015; 10 NNSB Nik Mohamed Kamal (1427_CR11) 2019; 10 G Rossi (1427_CR2) 2020; 12 SL Tung (1427_CR42) 2018; 8 T Shukuya (1427_CR14) 2020; 15 DH Kim (1427_CR61) 2021; 12 J Brahmer (1427_CR1) 2015; 373 IS Vlachos (1427_CR23) 2015; 43 Q Shi (1427_CR48) 2017; 20 Z-J Gao (1427_CR33) 2020; 9 R Zhou (1427_CR50) 2016; 6 F Bianchi (1427_CR67) 2020; 21 F-Q Dai (1427_CR32) 2019; 16 Y Xia (1427_CR59) 2020; 235 C Genova (1427_CR21) 2023; 12 Q-J Li (1427_CR45) 2007; 129 R Zhou (1427_CR51) 2015; 6 X-X Peng (1427_CR15) 2020; 8 H Peng (1427_CR54) 2016; 151 Y Hu (1427_CR13) 2020; 1248 S-L Zou (1427_CR36) 2019; 26 M Del Re (1427_CR17) 2018; 118 JW Leong (1427_CR46) 2014; 44 L Muller (1427_CR19) 2014; 411 H Jiang (1427_CR65) 2022; 13 Q Lin (1427_CR57) 2013; 107 W Li (1427_CR34) 2015; 10 S-B Ye (1427_CR62) 2014; 5 L-S Yang (1427_CR66) 2014; 34 KK Dobbin (1427_CR25) 2011; 4 F Cichocki (1427_CR69) 2020; 12 Q Ge (1427_CR18) 2014; 19 F Cichocki (1427_CR47) 2011; 187 H Schwarzenbach (1427_CR7) 2019; 5 AG Sacher (1427_CR4) 2016; 2 X Xu (1427_CR56) 2018; 7 K Hisakane (1427_CR16) 2023; 857 Y Zhang (1427_CR9) 2022; 173 E Rijavec (1427_CR6) 2019; 12 X-R Yang (1427_CR35) 2021; 38 |
| References_xml | – volume: 15 start-page: 1773 year: 2020 end-page: 1781 ident: CR14 article-title: Circulating microRNAs and extracellular vesicle-containing microRNAs as response biomarkers of anti-programmed cell death protein 1 or programmed death-ligand 1 therapy in NSCLC publication-title: J Thorac Oncol – ident: CR22 – volume: 14 start-page: 3412 year: 2022 ident: CR28 article-title: A circulating risk score, based on combined expression of exo-miR-130a-3p and fibrinopeptide A, as predictive biomarker of relapse in resectable non-small cell lung cancer patients publication-title: Cancers (Basel) – volume: 19 start-page: 1874 year: 2017 end-page: 1887 ident: CR68 article-title: A TLR3-specific adjuvant relieves innate resistance to PD-L1 blockade without cytokine toxicity in tumor vaccine immunotherapy publication-title: Cell Rep – volume: 9 start-page: 3060 year: 2018 ident: CR44 article-title: Regulation of miR-181a expression in T cell aging publication-title: Nat Commun – volume: 8 year: 2020 ident: CR31 article-title: Bringing microRNAs to light: methods for microRNA quantification and visualization in live cells publication-title: Front Bioeng Biotechnol – volume: 9 start-page: 104 year: 2020 end-page: 110 ident: CR33 article-title: miR-486 as an unfavorable prognostic biomarker for patients with non-small cell lung cancer publication-title: Transl Cancer Res – volume: 2016 start-page: 8394960 year: 2016 ident: CR27 article-title: Reprogramming of melanoma tumor-infiltrating lymphocytes to induced pluripotent stem cells publication-title: Stem Cells Int – volume: 12 start-page: 17 year: 2019 ident: CR6 article-title: Liquid biopsy in non-small cell lung cancer: highlights and challenges publication-title: Cancers (Basel) – volume: 5 start-page: 28 year: 2019 ident: CR7 article-title: MicroRNA shuttle from cell-to-cell by exosomes and its impact in cancer publication-title: Noncoding RNA – volume: 2020 start-page: 9601876 year: 2020 ident: CR49 article-title: Serum miR-1228–3p and miR-181a-5p as noninvasive biomarkers for non-small cell lung cancer diagnosis and prognosis publication-title: Biomed Res Int – volume: 26 start-page: 69 year: 2019 end-page: 77 ident: CR36 article-title: Downregulation of serum exosomal miR-150-5p is associated with poor prognosis in patients with colorectal cancer publication-title: Cancer Biomark – volume: 21 start-page: 1440 year: 2020 ident: CR67 article-title: TLR3 expression induces apoptosis in human non-small-cell lung cancer publication-title: Int J Mol Sci – volume: 13 start-page: 25 year: 2021 end-page: 35 ident: CR38 article-title: Identification of urinary exosomal miRNAs for the non-invasive diagnosis of prostate cancer publication-title: Cancer Manag Res – volume: 34 start-page: 342 year: 2014 end-page: 344 ident: CR66 article-title: Role of toll-like receptors in lung cancer publication-title: J Recept Signal Transduct Res – volume: 235 start-page: 6843 year: 2020 end-page: 6853 ident: CR59 article-title: Exosome-mediated transfer of miR-1260b promotes cell invasion through Wnt/β-catenin signaling pathway in lung adenocarcinoma publication-title: J Cell Physiol – volume: 173 start-page: 107 year: 2022 end-page: 115 ident: CR9 article-title: Machine learning-based exceptional response prediction of nivolumab monotherapy with circulating microRNAs in non-small cell lung cancer publication-title: Lung Cancer – volume: 10 start-page: 1500 year: 2019 ident: CR11 article-title: Non-exosomal and exosomal circulatory microRNAs: Which are more valid as biomarkers? publication-title: Front Pharmacol – volume: 6 start-page: 482 year: 2011 end-page: 488 ident: CR53 article-title: miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer publication-title: J Thorac Oncol – volume: 129 start-page: 147 year: 2007 end-page: 161 ident: CR45 article-title: miR-181a is an intrinsic modulator of T cell sensitivity and selection publication-title: Cell – volume: 8 start-page: 1566 year: 2019 ident: CR5 article-title: Correlation between B7–H4 and survival of non-small-cell lung cancer patients treated with nivolumab publication-title: J Clin Med – volume: 13 start-page: 6252 year: 2021 ident: CR41 article-title: miR-150-5p-containing extracellular vesicles are a new immunoregulator that favor the progression of lung cancer in hypoxic microenvironments by altering the phenotype of NK cells publication-title: Cancers (Basel) – volume: 7 start-page: 21 year: 2018 end-page: 31 ident: CR56 article-title: High circulating miR-18a, miR-20a, and miR-92a expression correlates with poor prognosis in patients with non-small cell lung cancer publication-title: Cancer Med – volume: 5 start-page: 5439 year: 2014 end-page: 5452 ident: CR62 article-title: Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma publication-title: Oncotarget – volume: 20 start-page: 545 year: 2019 ident: CR24 article-title: MIENTURNET: an interactive web tool for microRNA-target enrichment and network-based analysis publication-title: BMC Bioinform – volume: 113 start-page: 986 year: 2022 end-page: 1001 ident: CR37 article-title: Exosomes from M1-polarized macrophages promote apoptosis in lung adenocarcinoma via the miR-181a-5p/ETS1/STK16 axis publication-title: Cancer Sci – volume: 58 start-page: 376 year: 2019 end-page: 387 ident: CR60 article-title: Extracellular vesicle secretion of miR-142-3p from lung adenocarcinoma cells induces tumor promoting changes in the stroma through cell-cell communication publication-title: Mol Carcinog – volume: 17 start-page: 1428 year: 2020 end-page: 1438 ident: CR39 article-title: Tumor-derived circulating exosomal miR-342-5p and miR-574-5p as promising diagnostic biomarkers for early-stage Lung Adenocarcinoma publication-title: Int J Med Sci – volume: 44 start-page: 2862 year: 2014 end-page: 2868 ident: CR46 article-title: microRNA management of NK-cell developmental and functional programs publication-title: Eur J Immunol – volume: 8 year: 2020 ident: CR15 article-title: Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer publication-title: J Immunother Cancer – volume: 2 start-page: 1217 year: 2016 end-page: 1222 ident: CR4 article-title: Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review publication-title: JAMA Oncol – volume: 1248 start-page: 455 year: 2020 end-page: 483 ident: CR13 article-title: Exosome and secretion: action on? publication-title: Adv Exp Med Biol – volume: 10 year: 2015 ident: CR20 article-title: Characterization of RNA from exosomes and other extracellular vesicles isolated by a novel spin column-based method publication-title: PLoS ONE – volume: 23 start-page: 5311 year: 2017 end-page: 5319 ident: CR40 article-title: Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing publication-title: Clin Cancer Res – volume: 7 year: 2012 ident: CR52 article-title: MicroRNA-574-5p was pivotal for TLR9 signaling enhanced tumor progression via down-regulating checkpoint suppressor 1 in human lung cancer publication-title: PLoS ONE – volume: 13 start-page: 183 year: 2022 ident: CR65 article-title: M1 macrophage-derived exosomes and their key molecule lncRNA HOTTIP suppress head and neck squamous cell carcinoma progression by upregulating the TLR5/NF-κB pathway publication-title: Cell Death Dis – volume: 373 start-page: 1627 year: 2015 end-page: 1639 ident: CR3 article-title: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer publication-title: N Engl J Med – volume: 857 year: 2023 ident: CR16 article-title: Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer publication-title: Gene – volume: 13 year: 2022 ident: CR64 article-title: Mechanisms of MHC-I downregulation and role in immunotherapy response publication-title: Front Immunol – volume: 38 start-page: 109 year: 2021 end-page: 117 ident: CR35 article-title: Correlation of exosomal microRNA clusters with bone metastasis in non-small cell lung cancer publication-title: Clin Exp Metastasis – volume: 118 start-page: 820 year: 2018 end-page: 824 ident: CR17 article-title: PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC publication-title: Br J Cancer – volume: 18 start-page: 28 year: 2021 ident: CR43 article-title: miR-181a-regulated pathways in T-cell differentiation and aging publication-title: Immun Ageing – volume: 107 start-page: 767 year: 2013 end-page: 771 ident: CR57 article-title: Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer publication-title: J Surg Oncol – volume: 21 start-page: 585 year: 2020 end-page: 606 ident: CR55 article-title: RNA delivery by extracellular vesicles in mammalian cells and its applications publication-title: Nat Rev Mol Cell Biol – volume: 18 start-page: 40 year: 2019 ident: CR58 article-title: Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT publication-title: Mol Cancer – volume: 411 start-page: 55 year: 2014 end-page: 65 ident: CR19 article-title: Isolation of biologically-active exosomes from human plasma publication-title: J Immunol Methods – volume: 57 start-page: 1225 year: 2018 end-page: 1231 ident: CR8 article-title: Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab publication-title: Acta Oncol – volume: 10 year: 2015 ident: CR34 article-title: MicroRNA-486 as a biomarker for early diagnosis and recurrence of non-small cell lung cancer publication-title: PLoS ONE – volume: 373 start-page: 123 year: 2015 end-page: 135 ident: CR1 article-title: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer publication-title: N Engl J Med – volume: 8 start-page: 6065 year: 2018 ident: CR42 article-title: Regulatory T cell-derived extracellular vesicles modify dendritic cell function publication-title: Sci Rep – volume: 6 start-page: 44609 year: 2015 end-page: 44622 ident: CR51 article-title: Tumor invasion and metastasis regulated by microRNA-184 and microRNA-574-5p in small-cell lung cancer publication-title: Oncotarget – volume: 4 start-page: 31 year: 2011 ident: CR25 article-title: Optimally splitting cases for training and testing high dimensional classifiers publication-title: BMC Med Genomics – volume: 687 start-page: 113 year: 2011 end-page: 134 ident: CR30 article-title: Quantitation of microRNAs by real-time RT-qPCR publication-title: Methods Mol Biol – volume: 20 start-page: 539 year: 2017 end-page: 546 ident: CR48 article-title: MiR-181a inhibits non-small cell lung cancer cell proliferation by targeting CDK1 publication-title: Cancer Biomark – volume: 19 start-page: 1568 year: 2014 end-page: 1575 ident: CR18 article-title: miRNA in plasma exosome is stable under different storage conditions publication-title: Molecules – volume: 12 start-page: eaaz5618 year: 2020 ident: CR69 article-title: iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy publication-title: Sci Transl Med. – volume: 6 start-page: 19 year: 2022 ident: CR10 article-title: A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy publication-title: NPJ Precis Oncol – volume: 43 start-page: W460 year: 2015 end-page: 466 ident: CR23 article-title: DIANA-miRPath v3.0: deciphering microRNA function with experimental support publication-title: Nucleic Acids Res – volume: 111 start-page: 53900 year: 2016 ident: CR26 article-title: Exosomal miRNA analysis in non-small cell lung cancer (NSCLC) patients’ plasma through qPCR: a feasible liquid biopsy tool publication-title: J Vis Exp – volume: 12 start-page: 1125 year: 2020 ident: CR2 article-title: Precision medicine for NSCLC in the era of immunotherapy: new biomarkers to select the most suitable treatment or the most suitable patient publication-title: Cancers (Basel) – volume: 12 start-page: 747 year: 2021 ident: CR61 article-title: Exosomal miR-1260b derived from non-small cell lung cancer promotes tumor metastasis through the inhibition of HIPK2 publication-title: Cell Death Dis – volume: 22 start-page: 927 year: 2017 end-page: 936 ident: CR12 article-title: Exosomes: a new horizon in lung cancer publication-title: Drug Discov Today – volume: 6 start-page: 35714 year: 2016 ident: CR50 article-title: MicroRNA-574-5p promotes metastasis of non-small cell lung cancer by targeting PTPRU publication-title: Sci Rep – volume: 151 start-page: 235 year: 2016 end-page: 242 ident: CR54 article-title: A circulating non-coding RNA panel as an early detection predictor of non-small cell lung cancer publication-title: Life Sci – volume: 13 start-page: 358 year: 2012 end-page: 369 ident: CR29 article-title: MicroRNA profiling: approaches and considerations publication-title: Nat Rev Genet – volume: 187 start-page: 6171 year: 2011 end-page: 6175 ident: CR47 article-title: Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signaling publication-title: J Immunol – volume: 12 start-page: 832 year: 2023 ident: CR21 article-title: Prognostic role of soluble and extracellular vesicle-associated PD-L1, B7–H3 and B7–H4 in non-small cell lung cancer patients treated with immune checkpoint inhibitors publication-title: Cells – volume: 16 start-page: 675 year: 2019 end-page: 685 ident: CR32 article-title: miR-150-5p inhibits non-small-cell lung cancer metastasis and recurrence by targeting HMGA2 and β-catenin signaling publication-title: Mol Ther Nucleic Acids – volume: 17 start-page: 953 year: 2020 end-page: 964 ident: CR63 article-title: miR-19 regulates the expression of interferon-induced genes and MHC class I genes in human cancer cells publication-title: Int J Med Sci – volume: 38 start-page: 109 year: 2021 ident: 1427_CR35 publication-title: Clin Exp Metastasis doi: 10.1007/s10585-020-10062-y – volume: 173 start-page: 107 year: 2022 ident: 1427_CR9 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2022.09.004 – volume: 14 start-page: 3412 year: 2022 ident: 1427_CR28 publication-title: Cancers (Basel) doi: 10.3390/cancers14143412 – volume: 857 year: 2023 ident: 1427_CR16 publication-title: Gene doi: 10.1016/j.gene.2023.147177 – volume: 151 start-page: 235 year: 2016 ident: 1427_CR54 publication-title: Life Sci doi: 10.1016/j.lfs.2016.03.002 – ident: 1427_CR22 – volume: 13 start-page: 6252 year: 2021 ident: 1427_CR41 publication-title: Cancers (Basel) doi: 10.3390/cancers13246252 – volume: 7 year: 2012 ident: 1427_CR52 publication-title: PLoS ONE – volume: 18 start-page: 40 year: 2019 ident: 1427_CR58 publication-title: Mol Cancer doi: 10.1186/s12943-019-0959-5 – volume: 10 year: 2015 ident: 1427_CR20 publication-title: PLoS ONE doi: 10.1371/journal.pone.0136133 – volume: 687 start-page: 113 year: 2011 ident: 1427_CR30 publication-title: Methods Mol Biol doi: 10.1007/978-1-60761-944-4_8 – volume: 23 start-page: 5311 year: 2017 ident: 1427_CR40 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-0577 – volume: 18 start-page: 28 year: 2021 ident: 1427_CR43 publication-title: Immun Ageing doi: 10.1186/s12979-021-00240-1 – volume: 111 start-page: 53900 year: 2016 ident: 1427_CR26 publication-title: J Vis Exp – volume: 13 year: 2022 ident: 1427_CR64 publication-title: Front Immunol – volume: 2016 start-page: 8394960 year: 2016 ident: 1427_CR27 publication-title: Stem Cells Int doi: 10.1155/2016/8394960 – volume: 12 start-page: 832 year: 2023 ident: 1427_CR21 publication-title: Cells doi: 10.3390/cells12060832 – volume: 235 start-page: 6843 year: 2020 ident: 1427_CR59 publication-title: J Cell Physiol doi: 10.1002/jcp.29578 – volume: 17 start-page: 953 year: 2020 ident: 1427_CR63 publication-title: Int J Med Sci doi: 10.7150/ijms.44377 – volume: 13 start-page: 183 year: 2022 ident: 1427_CR65 publication-title: Cell Death Dis doi: 10.1038/s41419-022-04640-z – volume: 113 start-page: 986 year: 2022 ident: 1427_CR37 publication-title: Cancer Sci doi: 10.1111/cas.15268 – volume: 12 start-page: 747 year: 2021 ident: 1427_CR61 publication-title: Cell Death Dis doi: 10.1038/s41419-021-04024-9 – volume: 15 start-page: 1773 year: 2020 ident: 1427_CR14 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2020.05.022 – volume: 43 start-page: W460 year: 2015 ident: 1427_CR23 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkv403 – volume: 20 start-page: 545 year: 2019 ident: 1427_CR24 publication-title: BMC Bioinform doi: 10.1186/s12859-019-3105-x – volume: 8 start-page: 6065 year: 2018 ident: 1427_CR42 publication-title: Sci Rep doi: 10.1038/s41598-018-24531-8 – volume: 6 start-page: 19 year: 2022 ident: 1427_CR10 publication-title: NPJ Precis Oncol doi: 10.1038/s41698-022-00262-y – volume: 8 start-page: 1566 year: 2019 ident: 1427_CR5 publication-title: J Clin Med doi: 10.3390/jcm8101566 – volume: 10 start-page: 1500 year: 2019 ident: 1427_CR11 publication-title: Front Pharmacol doi: 10.3389/fphar.2019.01500 – volume: 12 start-page: 1125 year: 2020 ident: 1427_CR2 publication-title: Cancers (Basel) doi: 10.3390/cancers12051125 – volume: 19 start-page: 1874 year: 2017 ident: 1427_CR68 publication-title: Cell Rep doi: 10.1016/j.celrep.2017.05.015 – volume: 13 start-page: 25 year: 2021 ident: 1427_CR38 publication-title: Cancer Manag Res doi: 10.2147/CMAR.S272140 – volume: 129 start-page: 147 year: 2007 ident: 1427_CR45 publication-title: Cell doi: 10.1016/j.cell.2007.03.008 – volume: 5 start-page: 28 year: 2019 ident: 1427_CR7 publication-title: Noncoding RNA – volume: 373 start-page: 1627 year: 2015 ident: 1427_CR3 publication-title: N Engl J Med doi: 10.1056/NEJMoa1507643 – volume: 58 start-page: 376 year: 2019 ident: 1427_CR60 publication-title: Mol Carcinog doi: 10.1002/mc.22935 – volume: 26 start-page: 69 year: 2019 ident: 1427_CR36 publication-title: Cancer Biomark doi: 10.3233/CBM-190156 – volume: 12 start-page: 17 year: 2019 ident: 1427_CR6 publication-title: Cancers (Basel) doi: 10.3390/cancers12010017 – volume: 9 start-page: 104 year: 2020 ident: 1427_CR33 publication-title: Transl Cancer Res doi: 10.21037/tcr.2019.11.19 – volume: 118 start-page: 820 year: 2018 ident: 1427_CR17 publication-title: Br J Cancer doi: 10.1038/bjc.2018.9 – volume: 20 start-page: 539 year: 2017 ident: 1427_CR48 publication-title: Cancer Biomark doi: 10.3233/CBM-170350 – volume: 21 start-page: 585 year: 2020 ident: 1427_CR55 publication-title: Nat Rev Mol Cell Biol doi: 10.1038/s41580-020-0251-y – volume: 57 start-page: 1225 year: 2018 ident: 1427_CR8 publication-title: Acta Oncol doi: 10.1080/0284186X.2018.1465585 – volume: 373 start-page: 123 year: 2015 ident: 1427_CR1 publication-title: N Engl J Med doi: 10.1056/NEJMoa1504627 – volume: 17 start-page: 1428 year: 2020 ident: 1427_CR39 publication-title: Int J Med Sci doi: 10.7150/ijms.43500 – volume: 21 start-page: 1440 year: 2020 ident: 1427_CR67 publication-title: Int J Mol Sci doi: 10.3390/ijms21041440 – volume: 22 start-page: 927 year: 2017 ident: 1427_CR12 publication-title: Drug Discov Today doi: 10.1016/j.drudis.2017.03.004 – volume: 44 start-page: 2862 year: 2014 ident: 1427_CR46 publication-title: Eur J Immunol doi: 10.1002/eji.201444798 – volume: 5 start-page: 5439 year: 2014 ident: 1427_CR62 publication-title: Oncotarget doi: 10.18632/oncotarget.2118 – volume: 411 start-page: 55 year: 2014 ident: 1427_CR19 publication-title: J Immunol Methods doi: 10.1016/j.jim.2014.06.007 – volume: 9 start-page: 3060 year: 2018 ident: 1427_CR44 publication-title: Nat Commun doi: 10.1038/s41467-018-05552-3 – volume: 187 start-page: 6171 year: 2011 ident: 1427_CR47 publication-title: J Immunol doi: 10.4049/jimmunol.1100835 – volume: 4 start-page: 31 year: 2011 ident: 1427_CR25 publication-title: BMC Med Genomics doi: 10.1186/1755-8794-4-31 – volume: 16 start-page: 675 year: 2019 ident: 1427_CR32 publication-title: Mol Ther Nucleic Acids doi: 10.1016/j.omtn.2019.04.017 – volume: 8 year: 2020 ident: 1427_CR15 publication-title: J Immunother Cancer – volume: 19 start-page: 1568 year: 2014 ident: 1427_CR18 publication-title: Molecules doi: 10.3390/molecules19021568 – volume: 6 start-page: 44609 year: 2015 ident: 1427_CR51 publication-title: Oncotarget doi: 10.18632/oncotarget.6338 – volume: 13 start-page: 358 year: 2012 ident: 1427_CR29 publication-title: Nat Rev Genet doi: 10.1038/nrg3198 – volume: 107 start-page: 767 year: 2013 ident: 1427_CR57 publication-title: J Surg Oncol doi: 10.1002/jso.23312 – volume: 1248 start-page: 455 year: 2020 ident: 1427_CR13 publication-title: Adv Exp Med Biol doi: 10.1007/978-981-15-3266-5_19 – volume: 2020 start-page: 9601876 year: 2020 ident: 1427_CR49 publication-title: Biomed Res Int – volume: 12 start-page: eaaz5618 year: 2020 ident: 1427_CR69 publication-title: Sci Transl Med. doi: 10.1126/scitranslmed.aaz5618 – volume: 6 start-page: 482 year: 2011 ident: 1427_CR53 publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e318208c785 – volume: 8 year: 2020 ident: 1427_CR31 publication-title: Front Bioeng Biotechnol – volume: 6 start-page: 35714 year: 2016 ident: 1427_CR50 publication-title: Sci Rep doi: 10.1038/srep35714 – volume: 7 start-page: 21 year: 2018 ident: 1427_CR56 publication-title: Cancer Med doi: 10.1002/cam4.1238 – volume: 2 start-page: 1217 year: 2016 ident: 1427_CR4 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2016.0639 – volume: 34 start-page: 342 year: 2014 ident: 1427_CR66 publication-title: J Recept Signal Transduct Res doi: 10.3109/10799893.2014.903418 – volume: 10 year: 2015 ident: 1427_CR34 publication-title: PLoS ONE |
| SSID | ssj0015830 |
| Score | 2.4094236 |
| Snippet | Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced non-small cell lung cancer (NSCLC), although patient survival is still... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 182 |
| SubjectTerms | Adult Aged Aged, 80 and over Antineoplastic Agents, Immunological - therapeutic use Biomarkers, Tumor - genetics Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Copy number Disease control DNA microarrays Extracellular vesicles Extracellular Vesicles - genetics Extracellular Vesicles - metabolism Female Hematology Humans Immune checkpoint inhibitors Immune Checkpoint Inhibitors - therapeutic use Immunotherapy Internal Medicine L1 gene Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - mortality Lung Neoplasms - pathology Male Medicine Medicine & Public Health MicroRNAs - blood MicroRNAs - genetics Middle Aged Monoclonal antibodies Nivolumab - therapeutic use Non-small cell lung carcinoma Oncology Patients PD-L1 protein Prognosis Small cell lung carcinoma Targeted cancer therapy |
| Title | Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab |
| URI | https://link.springer.com/article/10.1007/s10238-024-01427-8 https://www.ncbi.nlm.nih.gov/pubmed/39105937 https://www.proquest.com/docview/3089862521 https://www.proquest.com/docview/3089513743 https://pubmed.ncbi.nlm.nih.gov/PMC11303437 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB7RVkJceD8CpTISN3DVxEkcH1fRlgpoD8BK5RTZjqOuoNlVs4sQv54Zx0nZFpB6iWTFVmxnxvONPfMZ4HWuZJPo2vEiMTlPYye5LlLFrZBJ4zmsDCUKH5_kR7P0_Wl2GpLCuiHafTiS9Cv1H8luaF442hR0f9ME19Yt2MnQQUF13Jm8-_phOp4eZIU4CAkyf2-5aYSuIcvrAZJXTkm98Tm8B7Oh233Mybf99crs219XGB1vOq77cDegUTbpxecB3HLtQ7h9HM7bH8Fy-hN7Rpv7FK3KfrjOR9Gx8_knnsmUZ0um29oX0YZrX-4YxXy1CyKAZucU_XPRsXnLTj6XH0sWeFw75iPcXc1oI5i1c79KavMYZofTL-URD3c0cJvKbIWLaWIaK-JaINQx6P0oaRs0-SZRTd6k6H81SiLMUwb12xGdGl0SmVud5YXTwoonsN0uWvcMGKqrsZRYkGtJ96IpZ-tEaqEaYs2LVQTx8NMqGwjM6R6N79Ul9TJNZYVTWfmprIoI3oxtlj19x39r7w6yUAVV7ipxUCh0-xDmRPBqfI1KSJOvW7dY93WyWCAai-BpLzrj54QiCCtkBMWGUI0ViOB78007P_NE3zEBjJSavh1E57Jf_x7G85tVfwF3Ei99KIT5LmyvLtbuJSKtldkLirUHW2Ve4nOWTH4DQZceog |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9QwDLdgk2AvE-NrhTGCxBtEWps2aR6natMx7u4BNmlvVZKm2kksd1pviD8fO9frdBsg8Rgl6Uccx3Zs_wzwUWrVZqbxvMys5HnqFTdlrrkTKmsjhpWlROHJVI4u8rPL4rKHyaFcmHv-e0pxQ6HCUZKg0ZtneKI-hm3yXBJOfiWrwWNQlOKoT4r587xNwfNAm3wYFHnPMxoFzukz2O01RXa8Iu0ePPLhOTyZ9L7wF7A4-YVPoIt3iiRlP30XI9zY9ewbL1TOiwUzoYlNlK8mtjtG8VhhTuDM7Joic246Ngts-r0aV6zHWO1YjD73DaNLWhZm8QQz9iVcnJ6cVyPe10_gLlfFEg-6zLZOpI1ANcSiZaKVa1Ec20y3ss3RNmq1QhVMW-Q9T1BnVMBROlPI0hvhxCvYCvPg94EhK1lHQf_SKKpZpr1rMmWEbgnRLtUJpOvFrV0PLk41Ln7Ud7DIRJAaCVJHgtRlAp-GOYsVtMY_Rx-saVb3bNbV4qjUaJKhCpLAh6EbGYQW3wQ_v12NKVKBmlICr1ckHl4nNKmXQiVQbhB_GEDg25s9YXYVQbhTEv45Tf283id33_X333jzf8Pfw9PR-WRcj79Mv76FnSzuZ9zW8gC2lje3_h1qREt7GFnhN_bl_qI |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dbxQhECdak8aXxm-3toqJb0raBXZZHptrL1Xbi1Ev6dsGWIiXtNyle238851h97Y9qyY-EmA_GIb5Dcz8IORdqVXgpvGs4rZkMveKmUpq5oTiIXFYWUwUPp2Ux1P56aw4u5XFn6LdV0eSXU4DsjTF5d6iCXu3Et_A1DCwL-AKSw7r7H3yQIKtxqCuKT8YzhGKSuz3qTJ_7rduju5gzLuhkr-dlyYzNH5Etnr8SA86gT8m93x8QjZP-xPyp2Rx9BOegNvxGF9Kr32b4t7oxewrK5RkxYKa2KQiWF2Tyi3FKK04R8pmeoHxOpctnUU6-TY6GdGeebWlKSbdNxS3bmmcpXXN2GdkOj76Pjpm_a0KzElVLGH54zY4kTcCwIkFf0UrF8BIW65DGSR4TEErAGbagkZ6JEDDax1LZ4qy8kY48ZxsxHn0LwkFBbMOUwFKo_AmM-1dw5UROiDPXa4zkq8Gt3Y95TjefHFe35Alo0BqEEidBFJXGXk_9Fl0hBv_bL2zklndK19bi_1Kg6MGwCQjb4dqUBscfBP9_KprU-QC8FNGXnQiHl4nNIJOoTJSrQl_aICU3Os1cfYjUXPnCAkkdv2wmic33_X339j-v-ZvyOaXw3F98nHy-RV5yNN0hlld7pCN5eWV3wWYtLSvkyb8AsN_Bxc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Extracellular+vesicles+miR-574-5p+and+miR-181a-5p+as+prognostic+markers+in+NSCLC+patients+treated+with+nivolumab&rft.jtitle=Clinical+and+experimental+medicine&rft.au=Genova%2C+Carlo&rft.au=Marconi%2C+Silvia&rft.au=Chiorino%2C+Giovanna&rft.au=Guana%2C+Francesca&rft.date=2024-08-06&rft.issn=1591-9528&rft.eissn=1591-9528&rft.volume=24&rft.issue=1&rft_id=info:doi/10.1007%2Fs10238-024-01427-8&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s10238_024_01427_8 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1591-9528&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1591-9528&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1591-9528&client=summon |